Completed PHASE4 INTERVENTIONAL 2-arm NCT03029169

Propafenone Versus Amiodarone in Septic Shock (PRASE)

Prospective Randomized Study of Efficacy and Safety of 1c Class Antiarrhythmic Agent (Propafenone) in Septic Shock

Sponsor: Charles University, Czech Republic

Conditions Septic Shock Supraventricular Arrhythmia

Interventions Amiodarone i.v. Propafenone i.v.

Updated 11 times since 2017 Last updated: Aug 1, 2022 Started: Oct 23, 2017 Primary completion: Jul 4, 2022 Completion: Aug 1, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Septic Shock and Supraventricular Arrhythmia and is currently completed. Charles University, Czech Republic leads this study, which shows 11 recorded versions since 2017 — indicating substantial longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

11 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE4
Sep 2024 — Sep 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Sep 2022 — Jul 2024 [monthly]

Completed PHASE4

Status: Recruiting → Completed
Jan 2021 — Sep 2022 [monthly]

Recruiting PHASE4

▶ Show 6 earlier versions

Sep 2020 — Jan 2021 [monthly]

Recruiting PHASE4
Sep 2019 — Sep 2020 [monthly]

Recruiting PHASE4
Sep 2018 — Sep 2019 [monthly]

Recruiting PHASE4
Jun 2018 — Sep 2018 [monthly]

Recruiting PHASE4
Feb 2018 — Jun 2018 [monthly]

Recruiting PHASE4

Status: Not Yet Recruiting → Recruiting
Feb 2017 — Feb 2018 [monthly]

Not Yet Recruiting PHASE4

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Charles University, Czech Republic

Data source: Charles University, Czech Republic

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Prague, Czechia